T-DM1 also exhibited lower risk of hematologic and cardiac toxicity when comparing with other second- or later-line therapies, suggesting excellent safety of T-DM1.The frequent SAEs of T-DM1 were thrombocytopenia (14%), increased AST (4%), anemia (4%), and increased ALT (3%) in EMILIA (50). This evidence concerns the gene GPT and anemia.